**Background of DPYSL5 Antibody**
The Dihydropyrimidinase-like 5 (DPYSL5) protein, also known as Collapsin Response Mediator Protein 5 (CRMP5), belongs to the CRMP family involved in neuronal development and cytoskeletal regulation. It plays a critical role in axon guidance, neurite outgrowth, and synaptic plasticity by modulating microtubule dynamics and signal transduction pathways. DPYSL5 is highly expressed in the nervous system and has been implicated in neurodevelopmental disorders, neurodegenerative diseases, and cancer.
DPYSL5 antibodies are immunological tools designed to detect and quantify this protein in research and diagnostic applications. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study DPYSL5's expression patterns, subcellular localization, and interactions. In cancer research, DPYSL5 antibodies help investigate its role in tumor progression, particularly in glioblastoma, lung cancer, and neuroblastoma, where altered DPYSL5 expression correlates with metastasis and poor prognosis.
These antibodies also contribute to understanding DPYSL5's post-translational modifications, such as phosphorylation, which regulate its function in neuronal and non-neuronal contexts. Additionally, DPYSL5 antibodies have potential clinical utility as biomarkers for disease diagnosis or therapeutic targeting. Their development and validation remain essential for elucidating DPYSL5's multifaceted roles in health and disease.